Plasma Fractionation Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Expansion of Private Donor Plasma Collection Centers

Global operators continue to accelerate site roll-outs to secure supply, reshaping the plasma fractionation market. CSL Plasma deployed the RIKA Plasma Donation System in Houston, trimming session times by 15 minutes and improving donor throughput. Canadian Blood Services is opening new centers—including Thunder Bay in early 2025—to increase domestic collections^{[1]CBC News, “Canadian Blood Services to Open Thunder Bay Plasma Centre,” cbc.ca}. Emerging economies are following suit; Indonesia’s first fractionation plant in Karawang will process 600,000 liters a year, converting discarded plasma into medicines. These moves collectively ease the raw-material bottleneck as global IG demand grows 8-9% annually. Larger, technology-enabled centers also allow companies to diversify sourcing and mitigate region-specific donor constraints, reinforcing supply resilience across the plasma fractionation market.

Rising Adoption of Subcutaneous Immunoglobulin (SCIG)

Patient preference for home therapy and pressure to lower infusion costs are driving rapid uptake of SCIG. XEMBIFY, the first FDA-cleared 20% SCIG for treatment-naïve primary immunodeficiency patients, offers ≥98% IgG purity and favorable tolerability. HYQVIA pairs 10% IG with recombinant hyaluronidase to achieve 93.3% bioavailability while requiring fewer infusion sites. These high-concentration products, alongside smart infusion pumps, facilitate self-administration and free hospital capacity. Payers view SCIG favorably because it reduces chair time and ancillary costs, supporting broader reimbursement. Consequently, specialty pharmacies and infusion centers are scaling distribution networks, reinforcing a structural shift toward decentralized care within the plasma fractionation market.

Increasing Albumin Utilization in Critical Care

Consensus guidance now recommends human serum albumin for fluid resuscitation in septic shock and perioperative management. Clinical experts in China, India and Indonesia emphasize albumin’s oncotic properties to stabilize hemodynamics and mitigate complications^{[2]HealthManagement.org Staff, “Expert Consensus on Albumin Use,” healthmanagement.org}. As healthcare infrastructure improves, Asia-Pacific hospitals are adopting standardized protocols, translating into higher albumin volumes. Local production initiatives, exemplified by Indonesia’s Karawang facility, aim to meet rising demand and reduce import dependence. Short-term growth is further supported by new evidence linking albumin supplementation to lower mortality in complex liver disease, widening its therapeutic scope. These trends collectively lift regional consumption, contributing to sustained expansion of the plasma fractionation market.

Government Funding for Hemophilia Treatment Programs

Public reimbursement schemes are broadening access to prophylactic replacement therapy, stabilizing demand for coagulation factors. Real-world data show comparable annualized bleeding rates between standard half-life and extended half-life products (1.7 vs 1.8 in hemophilia A; 2.1 vs 1.4 in hemophilia B), steering payers toward value-based procurement models. Pilot programs in Europe and Asia now incorporate quality-of-life metrics when allocating budgets, reinforcing steady uptake despite rising recombinant competition. Funding also covers comprehensive care centers that coordinate physiotherapy, psychosocial support and genetic counseling, driving holistic patient management. Such initiatives provide a predictable demand base, enabling manufacturers to optimize production lines and maintain economies of scale within the plasma fractionation market.

Supply Constraints Due to Donor Compensation Caps

Europe’s ethical ceilings on donor payments threaten supply stability, with forecasts pointing to a 4-8 million-liter shortfall by 2025. Imports already cover 40% of European demand, underscoring vulnerability to external shocks. The proposed Substances of Human Origin regulation seeks a balance between donor protection and material sufficiency, but near-term collection gaps persist. Australia, operating on voluntary donation, imported USD 399.2 million worth of immunoglobulin in 2022-23 as domestic volumes lagged 8% annual demand growth^{[3]ABC News, “Australia’s Growing Reliance on Imported Plasma,” abc.net.au}. These limitations compel fractionators to diversify sourcing, optimize yield per liter and invest in collection technology—yet they still temper growth projections for the plasma fractionation market.

Competition from Long-Acting Recombinant Coagulation Factors

Extended half-life recombinant factors and emerging gene therapies are redefining hemophilia management economics. Etranacogene dezaparvovec offers the prospect of durable correction with a single infusion, challenging lifetime plasma-derived factor consumption. Non-factor agents such as emicizumab further reduce bleeding episodes with subcutaneous dosing, enhancing adherence and patient convenience. With comparable clinical outcomes and supportive reimbursement in advanced markets, recombinant portfolios erode the addressable pool for plasma-derived coagulation factors. Although legacy products retain a role in inhibitor-positive or resource-constrained settings, competitive intensity weighs on segment profitability and moderates overall growth of the plasma fractionation market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Plasma Fractionation Market Segment Analysis

Immunoglobulins held 62.74% of the plasma fractionation market share in 2025, reflecting their broad therapeutic footprint in immunology and neurology. Launches of high-concentration formulations like Yimmugo are expected to lift segment revenues, with Grifols projecting USD 1 billion in U.S. sales over seven years. The plasma fractionation market benefits from stable double-digit demand for immunoglobulins, underpinned by expanding indications such as chronic inflammatory demyelinating polyneuropathy. At the same time, manufacturing upgrades—most notably Asahi Kasei Medical’s Planova FG1 filter—raise throughput and lower virus breakthrough risk, supporting volume growth.

Coagulation factors, while representing a smaller revenue base, are forecast to expand at a 8.97% CAGR, the fastest among product lines. Extended prophylaxis protocols foster rising per-patient consumption, and new delivery platforms improve adherence. Nevertheless, recombinant alternatives and non-factor therapies introduce pricing pressure. Albumin retains a sizeable share due to its role in critical care, especially across Asia-Pacific where protocol updates recommend early administration in septic shock. Protease inhibitors, centred on alpha-1 antitrypsin, are gaining momentum in pulmonology as standardized pathways for severe deficiency enter clinical practice. Taken together, product diversification and technological advancement continue to define competitive positioning in the plasma fractionation market.

Neurology applications accounted for 41.66% of 2025 revenues, anchored by intravenous and subcutaneous immunoglobulin use in CIDP and multifocal motor neuropathy. HYQVIA’s 93.3% bioavailability exemplifies modality evolution, offering fewer sites and lower infusion frequency. As disease awareness improves, diagnosis rates climb, further cementing neurology’s primacy in the plasma fractionation market. Growth is reinforced by real-world data demonstrating sustained functional gains and reduced relapse frequency with maintenance dosing.

Pulmonology marks the fastest-growing segment, slated to post a 10.12% CAGR to 2031. Alpha-1 antitrypsin replacement therapy drives this surge, with European consensus guidelines streamlining patient selection and dosing. Research linking arterial stiffness to cardiovascular risk in deficiency patients underscores wider systemic benefits, potentially unlocking new reimbursement pathways. Immunology remains a core indication set, while hematology confronts recombinant competition. Critical-care adoption of albumin in trauma and surgical contexts bolsters cross-department utilization, broadening application diversity. Collectively, these dynamics ensure the plasma fractionation market stays responsive to shifting clinical priorities.

Hospitals and clinics captured 69.35% of global revenues in 2025, reflecting their central role in administering intravenous therapies and managing acute indications. Complex infusion protocols, adverse-event monitoring and reimbursement pathways keep hospital pharmacies at the heart of the plasma fractionation market. As hospitals adopt integrated care pathways, utilization rates of albumin and coagulation factors rise, sustaining volume leadership. Investments in automated blood-component processors, including the Reveos system, enable transfusion services to cut processing steps by 65% and free resources for higher-value activities.

The “other end-users” category—which encompasses home care, specialty pharmacies and infusion suites—is projected to grow at 10.93% CAGR, powered by SCIG adoption and payer encouragement of home-based models. Improved training programs and remote monitoring technologies, such as connected pumps, enhance safety and adherence. Ambulatory surgical centers represent a niche yet expanding destination for albumin use in hemodynamic stabilization. Blood banks and plasma collection centers, while upstream, influence downstream availability by securing the raw material that sustains the plasma fractionation market.

Private players commanded 67.41% of 2025 revenues and exhibit the fastest growth trajectory at 8.18% CAGR. Octapharma’s plan to lift production capacity by 50% before 2028 typifies aggressive expansion strategies. These firms leverage flexible capital allocation, advanced IT infrastructure and global sourcing networks to optimize cost per liter and maintain quality. Vertically integrated models spanning donation through final fill-and-finish help private operators manage margins amid pricing pressure, securing competitive advantage in the plasma fractionation market.

Public fractionators remain pivotal in regions prioritizing self-sufficiency, albeit with more conservative investment horizons. Collaborations—such as Indonesia’s joint venture between the national sovereign wealth fund and SK Plasma—illustrate hybrid models that blend state oversight with private technological expertise. Technology-transfer agreements and contract manufacturing bolster public capacity without duplicating expensive R&D pipelines. Over the forecast period, blended ecosystems of private and public entities will continue to evolve, balancing access, affordability and strategic autonomy across the plasma fractionation market.

Geography Analysis

North America Plasma Fractionation Market

North America remains the epicenter of the plasma fractionation market, holding 53.05% of revenue in 2025. The United States alone accounts for 70% of global source plasma, supported by donor compensation that sustains a dense network of nearly 1,200 centers. The Congressional Plasma Caucus spotlights bipartisan support for uninterrupted immunoglobulin access, while technological upgrades like CSL’s RIKA system shorten donation times and improve throughput. Advanced regulatory processes facilitate rapid approval of next-generation filters and formulations, reinforcing the region’s supply chain robustness.

APAC Plasma Fractionation Market

Asia-Pacific represents the fastest-growing arena, anticipated to record a 9.18% CAGR to 2031. Governments in Indonesia, China and India are investing in domestic fractionation plants to reduce reliance on imports. Indonesia’s Karawang facility will convert 600,000 liters annually into high-value products, exemplifying a shift toward self-sufficiency. Nonetheless, supply imbalances persist: Australia imported USD 399.2 million worth of immunoglobulin in 2022-23, with demand growing 8% each year. Strategic transactions, such as CSL’s divestiture of its Wuhan plasma portfolio to Rongsheng Pharmaceutical for USD 185 million, realign footprints for better local market fit.

EMEA and LATAM Plasma Fractionation Market

Europe faces structural headwinds from donor compensation caps, leading to 40% dependence on U.S. plasma. Proposed SoHO regulations aim to boost donor retention while preserving ethical standards, yet near-term scarcity remains a reality. Manufacturing expertise and established distribution channels temper risk, but capacity utilization hinges on raw material flows. Latin America, the Middle East and Africa collectively contribute a modest share today, yet rising healthcare expenditure and wider insurance coverage are opening access to plasma-derived therapies. Long-term upside lies in infrastructure investment and public-private partnerships, gradually enlarging regional slices of the plasma fractionation market.

Regulatory Landscape

Regulation of plasma-derived medicinal products continues to tighten around donor safety, traceability, and quality management of source plasma. In the EU, the European Medicines Agency (EMA) retains Plasma Master File (PMF) certification as a key control for products supplied into the market. During 2026, EMA PMF lifecycle activity remained active for major fractionators via annual update re-certifications and variations, including PMF updates processed for CSL Behring and Takeda, and a Type IB PMF variation for Grifols. This reinforces the expectation of ongoing epidemiological surveillance, validated manufacturing controls, and documented change management across collection and fractionation.

In Europe, the Substances of Human Origin framework was strengthened with Regulation (EU) 2024/1938 (adopted June 2024), which treats plasma for fractionation as a critical SoHO and drives member-state actions aimed at adequacy and self-sufficiency while preserving ethical safeguards. Standards-setting also progressed globally: at the WHO Expert Committee on Biological Standardization (ECBS) meeting in April 2026, new and replacement international reference standards were established for blood coagulation factors, supporting more consistent potency and quality control testing of plasma-derived coagulation products across markets and manufacturers.

Market Opportunities and Future Outlook

Investments in yield-focused manufacturing are increasing headroom for immunoglobulins and other plasma-derived proteins, and they also create room for suppliers of enabling technologies (automation, virus filtration, and process intensification) that improve output per liter of plasma. In March 2026, CSL announced a USD 1.5 billion expansion of its Kankakee, Illinois plasma-therapy manufacturing facility, incorporating its Horizon 2 manufacturing process. In July 2026, Octapharma announced a USD 1.5 billion U.S. headquarters and manufacturing campus in Rock Hill, South Carolina. These projects support demand for equipment, consumables, and services that shorten batch cycles, improve yields, and raise domestic end-to-end capacity in major demand centers.

Regional self-sufficiency programs and new build-outs in EMEA and emerging markets also widen scaling routes beyond the traditional U.S.-centric plasma supply chain, aligning with Europe’s push under the SoHO framework. In May 2026, Kedrion announced a EUR 150 million expansion at its Bolognana, Italy site, targeting a tripling of annual processing capacity to 3.3 million liters by 2031. Grifols also moved forward on long-cycle capacity with a July 2025 announcement for a new Llicà de Vall, Spain facility backed by EUR 160 million. In parallel, PT SK Plasma Core Indonesia confirmed a USD 150 million Karawang facility scheduled to begin operations in early 2027, and SK Plasma started construction of a Turkey fractionation plant in a joint venture with the Turkish Red Crescent in June 2026, supporting local supply strategies and contract and technology-transfer pathways for fractionators and national blood organizations.